health partners glp 1 coverage GLP-1 in Employer Plans Could Nearly Double in 2024 Navigating Changes to GLP-1 Medication

Patients should be counseled that gastrointestinal symptoms usually improve within 48 weeks of reaching a stable dose

Many GLP-1 weight loss medications are considered for adults with obesity or adults with overweight and at least one weight-related health condition, such as high blood pressure, high cholesterol, type 2 diabetes risk, or similar metabolic concerns

These pathways are mainly located in arcuate nucleus of the hypothalamus (ARH)

But its not clear whether these benefits are from the drug or the weight loss

The new, compounded offering is notably cheaper than most injectable versions of GLP-1 drugs

Peer review Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work